Pimitespib

Pimitespib
Clinical data
Trade names	Jeselhy
Other names	TAS 116
Legal status
Legal status	Rx in Japan;
Identifiers
CAS Number	1260533-36-5;
UNII	PLO044MUDZ;
KEGG	D11920;
Chemical and physical data
Formula	C25H26N8O
Molar mass	454.538 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N)C1=CC=C(C(=C1)CC)N2N=C(C=3C2=NC=CC3N4C=NC(=C4)C=5C=NN(C5)C)C(C)C;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors.^[1] It was discovered and developed by Taiho Pharmaceutical Co.^[2] The mechanism of action of pimitespib involves inhibition of heat shock protein 90 (Hsp90).^[3]

In June 2022, it received approval in Japan for gastrointestinal stromal tumors that have progressed after chemotherapy.^[4]

References

^ "Pimitespib - Taiho Pharmaceutical". Adis Insight.
^ "Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)" (Press release). Taiho Pharmaceutical. June 20, 2022.
^ Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. (June 2022). "Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial". Annals of Oncology. 33 (9): 959–967. doi:10.1016/j.annonc.2022.05.518. PMID 35688358. S2CID 249532381.
^ Hoy SM (August 2022). "Pimitespib: First Approval". Drugs. 82 (13): 1413–1418. doi:10.1007/s40265-022-01764-6. PMID 35986838. S2CID 251672805.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "Pimitespib - Taiho Pharmaceutical". Adis Insight.

[2] "Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)" (Press release). Taiho Pharmaceutical. June 20, 2022.

[3] Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. (June 2022). "Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial". Annals of Oncology. 33 (9): 959–967. doi:10.1016/j.annonc.2022.05.518. PMID 35688358. S2CID 249532381.

[4] Hoy SM (August 2022). "Pimitespib: First Approval". Drugs. 82 (13): 1413–1418. doi:10.1007/s40265-022-01764-6. PMID 35986838. S2CID 251672805.

[1]

[2]

[3]

[4]